[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-563447-105":53,"doc-detail-563447-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","semaglutide-and-tirzepatide-for-obesity-effectiveness-and-value-draft-evidence-report","Semaglutide and Tirzepatide for Obesity - Effectiveness and Value - Draft Evidence Report","","Semaglutide and tirzepatide for obesity are assessed through an ICER draft evidence review focused on effectiveness and value. The report describes the evidence base used to support clinical and economic evaluations, including comparative effectiveness analyses and modeled cost-effectiveness and budget impact results. It also outlines author contributions, methods guidance, and disclosures, emphasizing transparency and separation from direct financial conflicts. Findings reflect the evidence available up to the publication date, with future updates possible as new data emerge.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/semaglutide-and-tirzepatide-for-obesity-effectiveness-and-value-draft-evidence-report/563447/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/semaglutide-and-tirzepatide-for-obesity-effectiveness-and-value-draft-evidence-report/563447.png","ImageObject",442,249,{"name":88,"@type":89},"Theodore","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-25","2026-10-12",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",6,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What is the purpose of the ICER draft evidence report on semaglutide and tirzepatide for obesity?","Question",{"text":109,"@type":110},"It provides an evidence-based evaluation of the effectiveness and value of semaglutide and tirzepatide for obesity, combining clinical comparisons with economic modeling to assess outcomes, costs, and cost-effectiveness.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"How is the economic analysis handled in ICER reports, according to the document?",{"text":114,"@type":110},"ICER economic models compare clinical outcomes and expected costs across care pathways, and results are presented as average findings across broad patient groups rather than predictions for any specific individual.",{"name":116,"@type":107,"acceptedAnswer":117},"Does the report’s evidence remain fixed after publication?",{"text":118,"@type":110},"No. The report states that evidence is current as of the publication date and new evidence may emerge that could influence results, with potential formal updates in the future.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},563447,1792093500,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":141,"read_time":142},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Semaglutide and Tirzepatide for Obesity: Effectiveness and Value  \nDraft Evidence Report  \nSEPTEMBER 9, 2025  \nPrepared for  \nAUTHORS: Grace A. Lin, MD  \nMedical Director for Health Technology Assessment  \nInstitute for Clinical and Economic Review  \nWoojung Lee, PharmD, PhD  \nAssociate Director of Health Economics and Decision Modeling Institute for Clinical and Economic Review  \nShahariar Mohammed Fahim, PhD, MSc  \nSenior Research Lead  \nInstitute for Clinical and Economic Review  \nMarina Richardson, PhD, MSc  \nAssociate Director, HTA Methods and Health Economics  \nInstitute for Clinical and Economic Review  \nMarie Phillips, BA  \nHealth Economics Research Assistant  \nInstitute for Clinical and Economic Review  \nFinn Raymond, BS  \nResearch Assistant  \nInstitute for Clinical and Economic Review  \nDavid Rind, MD, MSc  \nChief Medical Officer  \nInstitute for Clinical and Economic Review  \nICER’s value assessments are free from financial conflicts of interest from health care companies. Asan organization, we value transparency and hold ourselves, and our collaborators, to high standards for conducting our work. Our full policy to manage potential conflicts of interest can be found here. You can find ICER’s Code of Ethics here. Any conflicts reported by the authors of this report, contributing staff members, or expert reviewers, can be found on page vi.  \nDATE OF  \nPUBLICATION: September 9, 2025  \nHow to cite this document: Lin GA, Lee W, Fahim SM, Richardson M, Phillips M, Raymond F, Rind DM. Semaglutide and Tirzepatide for Obesity: Effectiveness and Value; Draft Evidence Report.  \nInstitute for Clinical and Economic Review, September 9, 2025. [https://icer.org/wp](https://icer.org/wp)content/uploads/2025/09/ICER Obesity Draft-Report For-Publication 090925. pdf  \nGrace Lin served as the lead author for the report. Shahariar Mohammed Fahim led the systematic review and authorship of the comparative effectiveness section of this report with assistance from Finn Raymond. Woojung Lee developed the cost-effectiveness model and authored corresponding sections of the report with support from Marina Richardson. Marie Phillips conducted the analysis for the budget impact model. David Rind provided methodologic guidance on the clinical and economic evaluations. We would also like to thank Becca Piltch, Anna Geiger, and Grace Ham for their contributions to this report.  \nAbout ICER  \nThe Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs. For more information about ICER, please visit ICER’s website.  \nThe funding for this report comes from non-profit foundations, with the largest single funder being the Arnold Ventures. No funding for this work comes from health insurers, pharmacy benefit managers (PBMs), or life science companies. ICER receives approximately 22% of its overall revenue from these health industry organizations to runa separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies. Life science companies relevant to this review who participate in this program include: Novo Nordisk. A complete list of funders and more information on ICER's support, is available on the funding page of the ICER website.  \nFor drug topics, in addition to receiving recommendations from the public, ICER scans publicly available information and also benefits from a collaboration with IPD Analytics, an independent organization that performs analyses of the emerging drug pi","cbCainMjWTl8Frqv","https://ap.wps.com/l/cbCainMjWTl8Frqv","pdf",10528887,224,"English","# Draft Evidence Report\n## Document citation and publication details\n## Author contributions and acknowledgements\n## About ICER\n## Funding and support disclosures\n## About NE CEPAC\n## Evidence currency and modeling limitations","[{\"question\":\"What is the purpose of the ICER draft evidence report on semaglutide and tirzepatide for obesity?\",\"answer\":\"It provides an evidence-based evaluation of the effectiveness and value of semaglutide and tirzepatide for obesity, combining clinical comparisons with economic modeling to assess outcomes, costs, and cost-effectiveness.\"},{\"question\":\"How is the economic analysis handled in ICER reports, according to the document?\",\"answer\":\"ICER economic models compare clinical outcomes and expected costs across care pathways, and results are presented as average findings across broad patient groups rather than predictions for any specific individual.\"},{\"question\":\"Does the report’s evidence remain fixed after publication?\",\"answer\":\"No. The report states that evidence is current as of the publication date and new evidence may emerge that could influence results, with potential formal updates in the future.\"}]","Semaglutide and Tirzepatide for Obesity - Effectiveness and Value - Draft Evidence Report | PDF",1791835503,78]